End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
20.46 CNY | -0.97% | +0.10% | -17.70% |
May. 13 | Humanwell Healthcare's Unit Gets Nod to Strengthen Oxycodone Hydrochloride Tablets' Dosage | MT |
Apr. 30 | Humanwell Healthcare's Q1 Profit Falls 27% | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-17.70% | 4.6B | B- | ||
+29.98% | 684B | C+ | ||
+30.34% | 568B | B | ||
-3.52% | 361B | C+ | ||
+18.59% | 329B | B- | ||
+4.07% | 284B | C+ | ||
+16.21% | 240B | B+ | ||
+9.66% | 208B | B- | ||
-6.83% | 200B | A+ | ||
+7.09% | 166B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600079 Stock
- Ratings Humanwell Healthcare (Group) Co.,Ltd.